{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:32:36Z","timestamp":1782761556273,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recently approved treatments for spinal muscular atrophy (SMA) may shift clinical care priorities to secondary complications associated with SMA-related aging. To date, there is little knowledge about the natural history of morbidities across the adult lifespan for SMA. The objective of this study was to identify the prevalence and odds ratio (OR) of various morbidities among adults with vs. without SMA prior to SMA-related treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study that accessed Medicare fee-for-service and commercial claims data from 01\/01\/2008-12\/22\/2016. Data from adults\u2009\u2265\u200918 years old with SMA and without SMA matched (1:200 case:control) on demographics, region, and study entry year were included. The prevalence of 30 morbidities across physiologic systems (e.g., cardiovascular, metabolic, musculoskeletal, urinary) and mental health disorders was examined. Age- and sex-adjusted OR was estimated using logistic regression for each morbidity and effect modification by age and sex was tested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 2,427 adults with SMA (mean [SD] age, 59.7 [17.4] years; 49.0% female) and 484,528 matched adults without SMA. Adults with vs. without SMA had a higher prevalence and adjusted OR of all 30 morbidities, ranging from OR\u2009=\u20091.61 (95% CI\u2009=\u20091.45\u20131.80) for hypothyroidism to OR\u2009=\u20097.80 (95% CI\u2009=\u20097.10\u20138.57) for fluid\/electrolyte disorders. There was effect modification by age for 24 morbidities. The OR was highest for the youngest age group (18\u201340 years; OR range, 2.38 to 117.7; all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and declined with older age groups, but still remained significantly elevated in the oldest age group (\u2265\u200975 years; OR range, 1.30 to 5.96; all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The limitations of this study are that evidence of morbidities were limited to diagnostic claims and information on SMA type and symptoms or onset were not available. In conclusion, adults with SMA had a higher and earlier prevalence of a variety of morbidities across physiological systems and mental health disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02872-6","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:31:22Z","timestamp":1693495882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of morbidities across the lifespan for adults with spinal muscular atrophy: a retrospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Daniel","family":"G. Whitney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"E. Neil Knierbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecia","family":"K. Daunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"1","key":"2872_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72,400 specimens. Eur J Hum Genet. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"2872_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2872_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"issue":"4","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"key":"2872_CR5","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.spen.2021.100878","volume":"37","author":"S Nicolau","year":"2021","unstructured":"Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal muscular atrophy. Semin Pediatr Neurol. 2021;37:100878.","journal-title":"Semin Pediatr Neurol"},{"issue":"8","key":"2872_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205\u201314.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2872_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16(3):265\u20139.","journal-title":"Nat Genet"},{"issue":"16","key":"2872_CR8","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","volume":"27","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Perenthaler E, Courtney NL, Jordan CY, Shorrock HK, van der Hoorn D, et al. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet. 2018;27(16):2851\u201362.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2872_CR9","doi-asserted-by":"publisher","first-page":"e0213680","DOI":"10.1371\/journal.pone.0213680","volume":"14","author":"SL Lipnick","year":"2019","unstructured":"Lipnick SL, Agniel DM, Aggarwal R, Makhortova NR, Finlayson SG, Brocato A, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE. 2019;14(3):e0213680.","journal-title":"PLoS ONE"},{"issue":"1","key":"2872_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JND-210764","volume":"10","author":"J Mouchet","year":"2023","unstructured":"Mouchet J, Roumpanis S, Gaki E, Lipnick S, Oskoui M, Scalco RS, et al. Disease Burden of spinal muscular atrophy: a comparative cohort study using insurance Claims Data in the USA. J Neuromuscul Dis. 2023;10(1):41\u201353.","journal-title":"J Neuromuscul Dis"},{"issue":"21","key":"2872_CR11","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013e506.","journal-title":"Neurology"},{"issue":"11","key":"2872_CR12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"10063","key":"2872_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"18","key":"2872_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"2872_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham Control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2872_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179\u201385.","journal-title":"Pediatr Pulmonol"},{"issue":"18","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"2872_CR18","doi-asserted-by":"publisher","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","volume":"8","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Kulas S, McGinnis E, Dabbous O, Jarecki J. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277.","journal-title":"J Mark Access Health Policy"},{"issue":"5","key":"2872_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"6","key":"2872_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2872_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"7","key":"2872_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dmcn.14879","volume":"63","author":"DG Whitney","year":"2021","unstructured":"Whitney DG, Basu T. Whitney Comorbidity Index to monitor health status for adults with cerebral palsy: validation and thresholds to assist clinical decision making. Dev Med Child Neurol. 2021;63(7):853\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"2872_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/dmcn.14759","volume":"63","author":"DG Whitney","year":"2021","unstructured":"Whitney DG, Kamdar NS. Development of a new comorbidity index for adults with cerebral palsy and comparative assessment with common comorbidity indices. Dev Med Child Neurol. 2021;63(3):313\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"2872_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1269547","volume":"34","author":"D Lambert","year":"1992","unstructured":"Lambert D. Zero-inflated Poisson Regression, with an application to defects in Manufacturing. Technometrics. 1992;34(1):1\u201314.","journal-title":"Technometrics"},{"issue":"4","key":"2872_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/165019701750300609","volume":"33","author":"P Vestergaard","year":"2001","unstructured":"Vestergaard P, Glerup H, Steffensen BF, Rejnmark L, Rahbek J, Moseklide L. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med. 2001;33(4):150\u20135.","journal-title":"J Rehabil Med"},{"issue":"15","key":"2872_CR26","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","volume":"94","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al. Population-based analysis of survival in spinal muscular atrophy. Neurology. 2020;94(15):e1634\u2013e44.","journal-title":"Neurology"},{"issue":"1","key":"2872_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA, Stam M, Otto LAM, Asselman FL, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis. 2020;15(1):88.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2872_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","volume":"19","author":"EP Armstrong","year":"2016","unstructured":"Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822\u20136.","journal-title":"J Med Econ"},{"issue":"10","key":"2872_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1212\/WNL.0b013e3182684707","volume":"79","author":"C St Germaine-Smith","year":"2012","unstructured":"St Germaine-Smith C, Metcalfe A, Pringsheim T, Roberts JI, Beck CA, Hemmelgarn BR, et al. Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology. 2012;79(10):1049\u201355.","journal-title":"Neurology"},{"issue":"sup1","key":"2872_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2021.2013676","volume":"24","author":"G Chen","year":"2021","unstructured":"Chen G, Sharif B, Gerber B, Farris MS, Cowling T, Cabalteja C, et al. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. J Med Econ. 2021;24(sup1):51\u20139.","journal-title":"J Med Econ"},{"issue":"1","key":"2872_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2872_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1651-2227.2008.01201.x","volume":"98","author":"E Arkblad","year":"2009","unstructured":"Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. 2009;98(5):865\u201372.","journal-title":"Acta Paediatr"},{"issue":"1","key":"2872_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0960-8966(99)00055-3","volume":"10","author":"N Darin","year":"2000","unstructured":"Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10(1):1\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2872_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0960-8966(92)90006-R","volume":"2","author":"L Merlini","year":"1992","unstructured":"Merlini L, Stagni SB, Marri E, Granata C. Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy. Neuromuscul Disord. 1992;2(3):197\u2013200.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2872_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1399-0004.1988.tb02854.x","volume":"34","author":"SE Tangsrud","year":"1988","unstructured":"Tangsrud SE, Halvorsen S. Child neuromuscular disease in southern Norway. Prevalence, age and distribution of diagnosis with special reference to non-duchenne muscular dystrophy. Clin Genet. 1988;34(3):145\u201352.","journal-title":"Clin Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02872-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:35:37Z","timestamp":1700314537000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02872-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02872-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Michigan Institutional Review Board approved this study (HUM00174549).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}